ASCO GI Conference Coverage

Eisai to Present Investigational Data on LENVIMA® (lenvatinib) Based Combination Therapies in Renal Cell Carcinoma at the 2021 Genitourinary Cancers Symposium

(Eisai) Jan 27, 2021 - Data will include a late-breaking oral presentation from the pivotal Phase 3 CLEAR study (KEYNOTE-581/Study 307) (NCT02811861) (Abstract # 269) evaluating KEYTRUDA plus LENVIMA and LENVIMA plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

read corporate press release

Triplet Shows 'Promising' Activity in Unresectable/Metastatic CRC

(Medscape Medical News) Jan 25, 2021 - Combining an EGFR inhibitor with a pair of checkpoint inhibitors can produce 'promising' activity in certain patients with colorectal cancer, according to an investigator from a phase 2 trial.

read article (free registration required)

RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium

(Yahoo! Finance) Jan 20, 2021 – RenovoRx today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment.

read article

GSK Presents Positive Efficacy Data Of Dostarlimab In Mismatch Repair-Deficient (dMMR) Solid Cancers at ASCO Gastrointestinal Cancers Symposium

(GSK) Jan 16, 2021 - GlaxoSmithKline plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid cancers being presented today at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). Study results (abstract #9) showed a 38.7% objective response rate (ORR) (N=106, 95% CI; 29.4–48.6) in patients with dMMR advanced solid cancers who received dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody. Additionally, after a median follow-up of 12.4 months, the median duration of response (DoR) had not yet been reached, and responses were durable across tumour types.

read corporate press release

Asco-GI 2021 Round-up – Cardiff Disappoints While Arcus Intrigues

(Evaluate Vantage) Jan 18, 2021 - Enhertu’s additional approval this morning for Her2-positive gastric cancer coincided with the Asco-GI conference, which featured a front-line gastric cancer study of Five Prime’s bemarituzumab as a late-breaker. The green light, the first for a Her2-directed therapy for this cancer since Herceptin, will also remind investors what the Astra/Daiichi drug has to do to meet expectations: EvaluatePharma consensus forecasts see 2026 sales of $4.1bn, mostly in breast cancer.

read article

GSK’s PD-1 Inhibitor Dostarlimab Shows Updated Promise in dMMR Solid Tumours

(PMLiVE [UK]) Jan 19, 2021 - GlaxoSmithKline’s dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. The updated data comes from cohort F of GSK's GARNET trial, which enrolled patients with mismatch repair-deficient (dMMR) non-endometrial advanced solid cancer tumours.

read article

Servier Announce Updated Overall Survival Results of Exploratory TASCO1 Phase II Study of LONSURF® + Bevacizumab In A First-line Setting For Patients With Unresectable mCRC Non-eligible For Intensive Therapy

(Yahoo! Finance) Jan 17, 2021 - Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.

read article

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

(NASDAQ) Jan 18, 2021 - Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively.

read article

Swift Uptake for Mvasi Suggests Provider Comfort With Use

(The Center For Biosimilars) Jan 18, 2021 - Investigators have demonstrated that initial uptake of the first bevacizumab biosimilar (Mvasi, Amgen) in the United States was strongest for patients receiving treatment for metastatic colorectal cancer (mCRC).

read article

New Target to Attack in Stomach Cancer

(MedPage Today) Jan 16, 2021 - Patients with untreated advanced gastric or gastroesophageal junction (GEJ) cancer lived longer without disease progression with the addition of a fibroblast growth factor receptor (FGFR) inhibitor to chemotherapy, a randomized trial showed. Median progression-free survival (PFS) increased from 7.4 months with chemotherapy alone to 9.5 months with bemarituzumab. The size of the PFS benefit increased with levels of FGFR2b expression. Median overall survival (OS) was 12.9 months with chemotherapy and not yet reached in patients who also received the FGFR2b inhibitor.

read article (free registration required)

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

(Agios) Jan 17, 2021 - Agios Pharmaceuticals, Inc. today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma. Data from the study were featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held virtually January 15-17, 2021.

read corporate press release

2021 GI Cancers Symposium: Ivosidenib Boosts Survival in IDH1-Mutated Cholangiocarcinoma

(OBR) Jan 17, 2021 - Ivosidenib added nearly three months to the median overall survival of previously treated patients with advanced IDH1-mutated cholangiocarcinoma (CCA), compared with placebo, according to findings reported at the American Society of Clinical Oncology’s 2021 Gastrointestinal Cancers Symposium. The favorable overall survival trend, which was not statistically significant, was reported as part of the final results from the ClarIDHy trial, a global phase 3 study examining the ivosidenib versus placebo for patients with unresectable or metastatic CCA and an IDH1 mutation (Abstract 266). After adjusting for the large percentage of patients on placebo who crossed over to ivosidenib treatment during the trial, the median overall survival difference improved and was statistically significant.

read article

2021 GI Cancers Symposium: Radiation Regimen Does Not Improve OS in Pancreatic Cancer Patients

(OBR) Jan 17, 2021 - Preoperative neoadjuvant modified FOLFIRINOX is associated with favorable overall survival (OS) rates in patients with borderline resectable pancreatic cancer, relative to historical data. But combining this therapy with hypofractionated radiation therapy (RT) was not as successful. Matthew Katz, MD, chief of the Pancreatic Surgery Service at the University of Texas MD Anderson Cancer Center, presented this research (Abstract 377) at the American Society of Clinical Oncology’s 2021 Gastrointestinal Cancers Symposium.

read article

2021 GI Cancers Symposium: Preop Therapy Does Not Raise Surgical Risks in Thoracic Esophageal Cancer

(OBR) Jan 16, 2021 - Adding docetaxel or radiotherapy to cisplatin plus 5-fluorouracil as preoperative therapy does not appear to increase the risk of perioperative complications or mortality in patients with locally advanced, potentially resectable thoracic esophageal cancer, according to findings reported at the American Society of Clinical Oncology’s 2021 Gastrointestinal Cancers Symposium. But the combination of cisplatin plus 5-fluorouracil with radiotherapy (CF-RT) did increase the risk of Grade 2 chylothorax after esophagectomy.

read article

2021 GI Cancers Symposium: Pembrolizumab Combo is Safe in Rectal Cancer, Fails to Improve NAR Score

(OBR) Jan 16, 2021 - A Phase 2 trial demonstrated the safety of adding pembrolizumab to neoadjuvant chemoradiation to treat locally advanced rectal cancer (LARC). However, it failed to meet a primary endpoint of improving the neoadjuvant rectal (NAR) score, which combines pathologic nodal status with tumor downstaging. Osama E. Rahma, MD, a medical oncologist at the Dana-Farber Cancer Institute in Boston, presented the results at ASCO’s 2021 Gastrointestinal Cancers Symposium (Abstract 8).

read article

ctDNA Emerges As an Early Harbinger of Postsurgical Recurrence in Patients With Stage I-III CRC

(ASCO Daily News) Jan 16, 2021 - Serial analysis of circulating tumor DNA (ctDNA) after surgery can identify patients with stage I-III colorectal cancer (CRC) at high risk for recurrence.

read article

Neoadjuvant mFOLFIRINOX Established as Reference Standard in Borderline Resectable PDAC

(ASCO Daily News) Jan 16, 2021 - Patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant therapy with modified FOLFIRINOX (mFOLFIRINOX) had an 18-month overall survival (OS) rate of 66.4% in a prospective phase II study conducted by the National Clinical Trials Network (Abstract 377).

read article

Updated 3-Year Results Confirm the Benefit of Adjuvant S-1 Plus Docetaxel for Stage III Gastric Cancer

(ASCO Daily News) Jan 15, 2021 - Updated data on the JACCRO GC-07 trial presented during the 2021 Gastrointestinal Cancers Symposium based on a median follow-up of 42.5 months not only confirmed the RFS results previously seen but documented a survival advantage as well (Abstract 159).

read article

The Gut Microbiome Offers Clues to Immunotherapy Efficacy in Advanced Gastric Cancer

(ASCO Daily News) Jan 15, 2021 - Findings from the observational DELIVER trial sponsored by the Japan Clinical Cancer Research Organization showed that patients with advanced gastric cancer who responded to nivolumab treatment had a more diverse gut microbiome compared with patients who did not respond to the immunotherapy (Abstract 161).

read article

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

(Yahoo! Finance) Jan 15, 2021 - Five Prime Therapeutics today announced clinical results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer. Trial results were presented in a late-breaking oral presentation today by UCLA Health’s Zev Wainberg, M.D., at the 2021 ASCO GI. The FIGHT trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus placebo plus chemotherapy in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), non HER2 positive frontline advanced gastric or GEJ cancer.

read article
Next Page